An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00528996
First received: September 12, 2007
Last updated: April 30, 2014
Last verified: April 2014
  Purpose

The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: BEA 2180 BR
Drug: tiotropium
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary endpoint in this study is trough FEV1 response after 24 weeks. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks [ Time Frame: after 1, 2, 4, 8, 12, and 18 weeks ] [ Designated as safety issue: No ]
  • Trough FVC (forced vital capacity) response after 1, 2, 4, 8, 12, 18, and 24 weeks [ Time Frame: after 1, 2, 4, 8, 12, 18, and 24 weeks ] [ Designated as safety issue: No ]
  • FEV1, FVC AUC0-3h and peak response after 0, 4, 12, and 24 weeks [ Time Frame: after 0, 4, 12, and 24 weeks ] [ Designated as safety issue: No ]
  • Individual FEV1 and FVC measurements at each time point [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • trough FEV1 response on Days 3 and 5 and FEV1 and FVC at 3 minutes and 10 minutes following drug administration [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Weekly mean pre-dose morning and evening PEFR (peak expiratory flow rate) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [salbuterol]) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Physician's Global Evaluation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Patient questionnaires: two Mahler Dyspnea Indices; St. George's Respiratory Questionnaire (SGRQ); and the SF-36 questionnaire [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Number of patients with at least one COPD exacerbation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Time to first exacerbation, as well as number of COPD exacerbations [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 2080
Study Start Date: September 2007
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
  2. All patients must have a diagnosis of chronic obstructive pulmonary disease (P95 4381) and must meet the following spirometric criteria:

    Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 (post-bronchodilator, 30 minutes post salbutamol/albuterol) <80% of predicted normal and FEV1 less than or equal to 70% of FVC at the PFTs at Visit 1 (screening).

  3. Male or female patients 40 years of age or older.
  4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.
  5. Patients must be able to perform technically acceptable pulmonary function tests and electronic PEFR measurements, and must be able to maintain records (Patient Daily Diary) during the study period as required in the protocol.
  6. Patients must be able to inhale medication in a competent manner from the Respimat® inhaler (Appendix I)

Exclusion Criteria:

  1. Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient ability to participate in the study.
  2. Patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a significant disease as defined in exclusion criterion No. 1.
  3. Patients with a recent history (one year or less) of myocardial infarction.
  4. Patients with any unstable or life-threatening cardiac arrhythmia.
  5. Patients who have been hospitalized for heart failure within the past 3 years.
  6. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
  7. Patients with known symptomatic prostatic hyperplasia or bladder neck obstruction as defined in exclusion criteria No. 1.
  8. Patients with known narrow-angle glaucoma.
  9. Patients with asthma or a history of asthma.
  10. Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
  11. Patients with known active tuberculosis.
  12. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion No. 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528996

  Hide Study Locations
Locations
United States, Alabama
1205.14.061 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States
1205.14.054 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
United States, California
1205.14.042 Boehringer Ingelheim Investigational Site
Berkeley, California, United States
1205.14.017 Boehringer Ingelheim Investigational Site
La Jolla, California, United States
1205.14.022 Boehringer Ingelheim Investigational Site
Lakewood, California, United States
1205.14.046 Boehringer Ingelheim Investigational Site
Riverside, California, United States
1205.14.047 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1205.14.008 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1205.14.037 Boehringer Ingelheim Investigational Site
Sepulveda, California, United States
United States, Colorado
1205.14.041 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1205.14.027 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado, United States
1205.14.034 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado, United States
United States, Connecticut
1205.14.050 Boehringer Ingelheim Investigational Site
Stamford, Connecticut, United States
United States, Florida
1205.14.013 Boehringer Ingelheim Investigational Site
Bay Pines, Florida, United States
1205.14.016 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1205.14.048 Boehringer Ingelheim Investigational Site
DeLand, Florida, United States
1205.14.043 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
1205.14.040 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
United States, Georgia
1205.14.007 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1205.14.053 Boehringer Ingelheim Investigational Site
Stockbridge, Georgia, United States
United States, Idaho
1205.14.014 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho, United States
United States, Kansas
1205.14.035 Boehringer Ingelheim Investigational Site
Olathe, Kansas, United States
United States, Louisiana
1205.14.057 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
1205.14.052 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
United States, Michigan
1205.14.036 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan, United States
1205.14.019 Boehringer Ingelheim Investigational Site
Livonia, Michigan, United States
United States, Missouri
1205.14.018 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri, United States
1205.14.032 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Nevada
1205.14.033 Boehringer Ingelheim Investigational Site
Reno, Nevada, United States
United States, New Jersey
1205.14.044 Boehringer Ingelheim Investigational Site
Brick, New Jersey, United States
1205.14.056 Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
1205.14.058 Boehringer Ingelheim Investigational Site
Summit, New Jersey, United States
United States, New Mexico
1205.14.010 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
United States, New York
1205.14.062 Boehringer Ingelheim Investigational Site
Larchmont, New York, United States
1205.14.028 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
1205.14.030 Boehringer Ingelheim Investigational Site
New Hyde Park, New York, United States
1205.14.021 Boehringer Ingelheim Investigational Site
New York, New York, United States
United States, Ohio
1205.14.059 Boehringer Ingelheim Investigational Site
Toledo, Ohio, United States
United States, Oklahoma
1205.14.012 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
United States, Oregon
1205.14.031 Boehringer Ingelheim Investigational Site
Medford, Oregon, United States
United States, Pennsylvania
1205.14.003 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1205.14.004 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
1205.14.005 Boehringer Ingelheim Investigational Site
Johnston, Rhode Island, United States
United States, South Carolina
1205.14.029 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1205.14.055 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1205.14.020 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
United States, Texas
1205.14.045 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1205.14.025 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1205.14.060 Boehringer Ingelheim Investigational Site
Killeen, Texas, United States
1205.14.002 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
United States, Virginia
1205.14.023 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
1205.14.024 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
1205.14.026 Boehringer Ingelheim Investigational Site
Roanoke, Virginia, United States
United States, Washington
1205.14.009 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1205.14.039 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
United States, West Virginia
1205.14.001 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia, United States
Canada, Alberta
1205.14.151 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
Canada, British Columbia
1205.14.144 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Canada, Newfoundland and Labrador
1205.14.148 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
Canada, Ontario
1205.14.143 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1205.14.142 Boehringer Ingelheim Investigational Site
Downsview, Ontario, Canada
1205.14.150 Boehringer Ingelheim Investigational Site
Grimsby, Ontario, Canada
1205.14.149 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
Canada, Quebec
1205.14.145 Boehringer Ingelheim Investigational Site
Sherbrooke, Quebec, Canada
Canada
1205.14.146 Boehringer Ingelheim Investigational Site
Quebec, Canada
Germany
1205.14.381 Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
1205.14.164 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.177 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.387 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.388 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.168 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.167 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.382 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.172 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.377 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.175 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.178 Boehringer Ingelheim Investigational Site
Berlin, Germany
1205.14.165 Boehringer Ingelheim Investigational Site
Bonn, Germany
1205.14.176 Boehringer Ingelheim Investigational Site
Cottbus, Germany
1205.14.171 Boehringer Ingelheim Investigational Site
Dortmund, Germany
1205.14.379 Boehringer Ingelheim Investigational Site
Geesthacht, Germany
1205.14.174 Boehringer Ingelheim Investigational Site
Gelnhausen, Germany
1205.14.173 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1205.14.375 Boehringer Ingelheim Investigational Site
Hannover, Germany
1205.14.378 Boehringer Ingelheim Investigational Site
Koblenz, Germany
1205.14.170 Boehringer Ingelheim Investigational Site
Lübeck, Germany
1205.14.162 Boehringer Ingelheim Investigational Site
Mainz, Germany
1205.14.384 Boehringer Ingelheim Investigational Site
Marburg, Germany
1205.14.166 Boehringer Ingelheim Investigational Site
Minden, Germany
1205.14.372 Boehringer Ingelheim Investigational Site
Neumünster, Germany
1205.14.386 Boehringer Ingelheim Investigational Site
Neuruppin, Germany
1205.14.385 Boehringer Ingelheim Investigational Site
Oschersleben, Germany
1205.14.169 Boehringer Ingelheim Investigational Site
Rüdersdorf, Germany
1205.14.179 Boehringer Ingelheim Investigational Site
Rüsselsheim, Germany
1205.14.376 Boehringer Ingelheim Investigational Site
Saarbrücken, Germany
1205.14.374 Boehringer Ingelheim Investigational Site
Schwetzingen, Germany
1205.14.373 Boehringer Ingelheim Investigational Site
Witten, Germany
1205.14.371 Boehringer Ingelheim Investigational Site
Witten, Germany
Hungary
1205.14.279 Boehringer Ingelheim Investigational Site
Budakeszi, Hungary
1205.14.273 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1205.14.283 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1205.14.287 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1205.14.286 Boehringer Ingelheim Investigational Site
Cegled, Hungary
1205.14.281 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
1205.14.272 Boehringer Ingelheim Investigational Site
Deszk, Hungary
1205.14.289 Boehringer Ingelheim Investigational Site
Deszk, Hungary
1205.14.271 Boehringer Ingelheim Investigational Site
Erd, Hungary
1205.14.282 Boehringer Ingelheim Investigational Site
Gyula, Hungary
1205.14.276 Boehringer Ingelheim Investigational Site
Gödöllö, Hungary
1205.14.277 Boehringer Ingelheim Investigational Site
Komarom, Hungary
1205.14.278 Boehringer Ingelheim Investigational Site
Matrahaza, Hungary
1205.14.280 Boehringer Ingelheim Investigational Site
Mosonmagyarovar, Hungary
1205.14.285 Boehringer Ingelheim Investigational Site
Sopron, Hungary
1205.14.275 Boehringer Ingelheim Investigational Site
Szarvas, Hungary
1205.14.288 Boehringer Ingelheim Investigational Site
Szazhalombatta, Hungary
1205.14.284 Boehringer Ingelheim Investigational Site
Tatabanya, Hungary
1205.14.274 Boehringer Ingelheim Investigational Site
Zalaegerszeg, Hungary
Korea, Republic of
1205.14.225 Boehringer Ingelheim Investigational Site
Gyeonggi-do, Korea, Republic of
1205.14.228 Boehringer Ingelheim Investigational Site
Gyeonggi-do, Korea, Republic of
1205.14.227 Boehringer Ingelheim Investigational Site
Seongdong-gu, Korea, Republic of
1205.14.224 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1205.14.222 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1205.14.226 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1205.14.221 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1205.14.223 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Mexico
1205.14.117 Boehringer Ingelheim Investigational Site
Ciudad de Mexico, Mexico
1205.14.108 Boehringer Ingelheim Investigational Site
Cuernavaca, Mor. México, Mexico
1205.14.101 Boehringer Ingelheim Investigational Site
Hermosillo, Sonora, Mexico
1205.14.119 Boehringer Ingelheim Investigational Site
Metepec, Mexico
1205.14.120 Boehringer Ingelheim Investigational Site
Mexico City, Mexico
1205.14.102 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1205.14.116 Boehringer Ingelheim Investigational Site
Monterrey, Nuevo León, Mexico
1205.14.105 Boehringer Ingelheim Investigational Site
Zapopan, Jal., Mexico
Poland
1205.14.251 Boehringer Ingelheim Investigational Site
Chrzanow, Poland
1205.14.253 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1205.14.254 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1205.14.246 Boehringer Ingelheim Investigational Site
Krakow, Poland
1205.14.242 Boehringer Ingelheim Investigational Site
Lodz, Poland
1205.14.241 Boehringer Ingelheim Investigational Site
Lodz, Poland
1205.14.255 Boehringer Ingelheim Investigational Site
Miechow, Poland
1205.14.248 Boehringer Ingelheim Investigational Site
Ruda Slaska, Poland
1205.14.249 Boehringer Ingelheim Investigational Site
Tarnowskie Gory, Poland
1205.14.252 Boehringer Ingelheim Investigational Site
Wilkowice, Poland
1205.14.245 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
1205.14.244 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
1205.14.243 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
1205.14.247 Boehringer Ingelheim Investigational Site
Zabrze, Poland
Russian Federation
1205.14.302 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.301 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.304 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.305 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.306 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.303 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1205.14.310 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1205.14.311 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1205.14.312 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1205.14.313 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1205.14.314 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1205.14.307 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
1205.14.309 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
1205.14.308 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Spain
1205.14.182 Boehringer Ingelheim Investigational Site
Badajoz, Spain
1205.14.186 Boehringer Ingelheim Investigational Site
Cáceres, Spain
1205.14.183 Boehringer Ingelheim Investigational Site
Madrid, Spain
1205.14.191 Boehringer Ingelheim Investigational Site
Málaga, Spain
1205.14.181 Boehringer Ingelheim Investigational Site
Terrassa (Barcelona), Spain
1205.14.190 Boehringer Ingelheim Investigational Site
Torrevieja, Spain
1205.14.189 Boehringer Ingelheim Investigational Site
Valencia, Spain
1205.14.187 Boehringer Ingelheim Investigational Site
Vigo, Spain
Taiwan
1205.14.207 Boehringer Ingelheim Investigational Site
Changhua, Taiwan
1205.14.208 Boehringer Ingelheim Investigational Site
Chiayi City, Taiwan
1205.14.210 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1205.14.209 Boehringer Ingelheim Investigational Site
Kaohsiung County, Taiwan
1205.14.205 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1205.14.206 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1205.14.202 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1205.14.204 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1205.14.201 Boehringer Ingelheim Investigational Site
Taoyuan County, Taiwan
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00528996     History of Changes
Other Study ID Numbers: 1205.14, 2007-007946-42
Study First Received: September 12, 2007
Last Updated: April 30, 2014
Health Authority: Canada: Therapeutic Products Directorate branch of Health Canada
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy (OGYI), H-1051 Budapest
Korea, Republic of: KOREA Food and Drug Administration (KFDA)
Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)
Poland: CEBK, Warsaw
Russia: Ministry of Healthcare and Social Development of Russian Federation, Moscow
Spain: Spanish Medicines and Healthcare Products Agency
Taiwan: Department of Health, Executive Yuan, Taiwan
United States: Food and Drug Administration

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014